J&J invests $500m into global HIV and TB treatment
10-10-2019
J&J reveals plans to appeal cancer drug court ruling
29-10-2018
PTAB invalidates Johnson & Johnson cancer drug patent
18-01-2018
Gil C / Shutterstock.com
The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson (J&J) on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga (abiraterone acetate).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Johnson & Johnson, US Court of Appeals for the Federal Circuit, US Patent and Trial Appeal Board, Zytiga, prostate cancer drug, patent invalidation
